We are live on !
Find out more
Gates Foundation Portfolio holdings
AUM
$43.5M
Turnover
0%
1-Year Est. Return
14.19%
This Fund
S&P 500
This Quarter Est. Return
-9.02%
1 Year Est. Return
+14.19%
3 Year Est. Return
-58.08%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$40.2M
AUM Growth
-$43.9M
(-52%)
Cap. Flow
-$37.7M
Cap. Flow % of AUM
Cap. Flow %
-93.78%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
–
Reduced
–
Closed
3
Avg Time Held
3.3
years
Top 10 Avg Time Held
3.3
years
Top 20 Avg Time Held
3.3
years
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Immunocore
IMCR
|
+$37.5M |
| 2 |
LMDX
LumiraDx
LMDX
|
+$143K |
| 3 |
BCEL
Atreca
BCEL
|
+$73K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
GF
BCP
Gates Foundation's Q2 2024 Portfolio in Review
As of Q2 2024, Gates Foundation held 8 positions worth $40.2M, down 52% from $84.1M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Gates Foundation withdrew a net $37.7M in Q2 2024, closing 3 positions. Its most notable exit was Immunocore, an estimated $37.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Gates Foundation fully exited Immunocore in Q2 2024, selling an estimated $37.5M.
- Gates Foundation's ten largest holdings make up 100% of its $40.2M portfolio in Q2 2024.
- Gates Foundation opened 0 new positions and closed 3 in Q2 2024.
- Gates Foundation's portfolio value fell 52% quarter-over-quarter to $40.2M.
Based on Gates Foundation's 13F filing for Q2 2024, filed 14 Aug 2024.